Gain Therapeutics Doses First Participant in Phase 1b Clinical Trial of GT-02287

(PR-inside.com) Interim Analysis Expected End of 2Q 2025 BETHESDA, MD, Mar 14, 2025 - (ACN Newswire) - Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced the dosing of the first participant with Parkinson’s